Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coya Therapeutics (COYA) Change in Account Payables (2022 - 2025)

Coya Therapeutics' Change in Account Payables history spans 4 years, with the latest figure at $180358.0 for Q3 2025.

  • For Q3 2025, Change in Account Payables rose 112.1% year-over-year to $180358.0; the TTM value through Sep 2025 reached $774980.0, up 360.73%, while the annual FY2024 figure was $477450.0, 59.78% up from the prior year.
  • Change in Account Payables for Q3 2025 was $180358.0 at Coya Therapeutics, up from -$758663.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $1.3 million in Q4 2024 and bottomed at -$1.5 million in Q3 2024.
  • The 4-year median for Change in Account Payables is $180358.0 (2025), against an average of $76341.6.
  • The largest annual shift saw Change in Account Payables skyrocketed 654.03% in 2023 before it crashed 475.92% in 2024.
  • A 4-year view of Change in Account Payables shows it stood at $389106.0 in 2022, then grew by 22.52% to $476727.0 in 2023, then skyrocketed by 162.5% to $1.3 million in 2024, then tumbled by 85.59% to $180358.0 in 2025.
  • Per Business Quant, the three most recent readings for COYA's Change in Account Payables are $180358.0 (Q3 2025), -$758663.0 (Q2 2025), and $101879.0 (Q1 2025).